Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California.
Cancer. 2021 May 15;127(10):1590-1597. doi: 10.1002/cncr.33414. Epub 2021 Feb 17.
Modern disease staging systems have restructured human papillomavirus (HPV)-negative (HPV-) and HPV-positive (HPV+) oropharyngeal carcinoma (OPC) into distinct pathologic nodal systems. Given that quantitative lymph node (LN) burden is the dominant prognostic factor in most head and neck cancers, we investigated whether HPV- and HPV+ OPC warrant divergent pathologic nodal classification.
Multivariable Cox regression models of OPC surgical patients identified via U.S. cancer registry data were constructed to determine associations between survival and nodal characteristics. Nonlinear associations between metastatic LN number and survival were modeled with restricted cubic splines. Recursive partitioning analysis (RPA) was used to derive unbiased nodal schema.
Mortality risk escalated continuously with each successive positive LN in both OPC subtypes, with analogous slope. Survival hazard increased by 18.5% (hazard ratio [HR], 1.19 [95% CI, 1.16-1.21]; P < .001) and 19.1% (HR, 1.19 [95% CI, 1.17-1.21]; P < .001), with each added positive LN for HPV- and HPV+ OPC, respectively, up to identical change points of 5 positive LNs. Extranodal extension (ENE) was an independent predictor of HPV- OPC (HR, 1.55 [95% CI, 1.20-1.99]; P < .001) and HPV+ OPC (HR 1.73 [95% CI, 1.36-2.20]; P < .001) mortality. In RPA for both diseases, metastatic LN was the principal nodal covariate driving survival, with ENE as a secondary determinant. Given the similarities across analyses, we propose a concise, unifying HPV-/HPV+ OPC pathologic nodal classification schema: N1, 1-5 LN+/ENE-; N2, 1-5 LN+/ENE+; N3, >5 LN+.
HPV- and HPV+ OPC exhibit parallel relationships between nodal characteristics and relative mortality. In both diseases, metastatic LN number represents the principal nodal covariate governing survival, with ENE being an influential secondary element. A consolidated OPC pathologic nodal staging system that is based on these covariates may best convey prognosis.
The current nodal staging system for oropharyngeal carcinoma (OPC) has divided human papillomavirus (HPV)-negative (HPV-) and HPV-positive (HPV+) OPC into distinct systems that rely upon criteria that establish them as separate entities, a complexity that may undermine the core objective of staging schema to clearly communicate prognosis. Our large-scale analysis revealed that HPV- and HPV+ pathologic nodal staging systems in fact mirror each other. Multiple analyses produced conspicuously similar nodal staging systems, with metastatic lymph node number and extranodal extension delineating the highest risk groups that shape prognosis. We propose unifying HPV- and HPV+ nodal systems to best streamline prognostication and maximize staging accuracy.
现代疾病分期系统将人乳头瘤病毒(HPV)阴性(HPV-)和 HPV 阳性(HPV+)口咽癌(OPC)重新划分为不同的病理淋巴结系统。鉴于定量淋巴结(LN)负担是大多数头颈部癌症的主要预后因素,我们研究了 HPV-和 HPV+ OPC 是否需要不同的病理淋巴结分类。
使用美国癌症登记处数据构建了 OPC 手术患者的多变量 Cox 回归模型,以确定生存与淋巴结特征之间的关联。使用受限立方样条对转移性 LN 数量与生存之间的非线性关系进行建模。递归分区分析(RPA)用于推导出无偏的淋巴结方案。
在两种 OPC 亚型中,每增加一个阳性 LN,死亡率都会连续上升,斜率相似。HPV-和 HPV+ OPC 中,每个阳性 LN 分别增加 18.5%(风险比[HR],1.19[95%CI,1.16-1.21];P<0.001)和 19.1%(HR,1.19[95%CI,1.17-1.21];P<0.001),风险增加,直到相同的 5 个阳性 LN 变化点。淋巴结外扩散(ENE)是 HPV-OPC(HR,1.55[95%CI,1.20-1.99];P<0.001)和 HPV+OPC(HR,1.73[95%CI,1.36-2.20];P<0.001)死亡的独立预测因子。在 RPA 中,两种疾病的转移性 LN 是驱动生存的主要淋巴结变量,ENE 是次要决定因素。鉴于分析结果的相似性,我们提出了一个简洁、统一的 HPV-/HPV+ OPC 病理淋巴结分类方案:N1,1-5 个 LN+/ENE-;N2,1-5 个 LN+/ENE+;N3,>5 个 LN+。
HPV-和 HPV+ OPC 的淋巴结特征与相对死亡率之间存在平行关系。在两种疾病中,转移性 LN 数量是决定生存的主要淋巴结变量,ENE 是一个有影响的次要因素。基于这些变量的综合 OPC 病理淋巴结分期系统可能是预后的最佳指标。
目前的口咽癌(OPC)淋巴结分期系统将人乳头瘤病毒(HPV)阴性(HPV-)和 HPV 阳性(HPV+)OPC 分为不同的系统,这些系统依赖于将它们确定为独立实体的标准,这种复杂性可能会破坏分期系统的核心目标,即清晰地传达预后。我们的大规模分析表明,HPV-和 HPV+的病理淋巴结分期系统实际上是相互镜像的。多项分析产生了明显相似的淋巴结分期系统,转移性淋巴结数量和淋巴结外扩散(ENE)划定了最高风险组,从而影响预后。我们提出了统一 HPV-和 HPV+淋巴结系统的方案,以更好地简化预后预测并最大限度地提高分期准确性。